@article{35339f13e7cd4e78b8d0af1990b54cb3,
title = "Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on {\textquoteleft}Tofacitinib for polyarteritis nodosa: a tailored therapy{\textquoteright} by Rimar et al",
author = "Mitsuhiro Akiyama and Yuko Kaneko and Tsutomu Takeuchi",
note = "Funding Information: MA reports no conflicts of interest relevant to this article. YK has received grants or speaker fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi and UCB. TT has received research grants or speaking fees from Astellas Pharma Inc, Bristol–Myers KK, Chugai Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Takeda Pharmaceutical Co, Ltd, Teijin Pharma Ltd, AbbVie GK, Asahi Kasei Pharma Corp, Mitsubishi Tanabe Pharma, Astra Zeneca KK, Eli Lilly Japan KK, Novartis Pharma KK, AbbVie GK, Nippon Kayaku Co Ltd, Janssen Pharmaceutical KK, Taiho Pharmaceutical Co, Ltd and Pfizer Japan Inc. ",
year = "2020",
month = sep,
day = "9",
doi = "10.1136/annrheumdis-2020-218710",
language = "English",
volume = "81",
pages = "E204",
journal = "Annals of the rheumatic diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "10",
}